Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16044005 | 0.80 | PIK3CA (0.41) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL28548161 | 0.80 | PIK3CD (0.48) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL17959848 | 0.78 | ERN1 (0.44) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL5584076 | 0.75 | AHR (0.35) | — | |
| SCHEMBL1032066 | 0.74 | MKNK1 (0.44) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL17436998 | 0.71 | KCNH2 (0.59) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL14947690 | 0.71 | DYRK1A (0.46) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL17794670 | 0.71 | KCNH2 (0.46) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL31107039 | 0.71 | DYRK1A (0.46) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL15950986 | 0.71 | KCNH2 (0.66) | FGFR3KDRACVR1BRD4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1391476-A | Vasopressin agonist formulation and process | AMERICAN CYANAMID CO (US) | 2003-01-15 | — | — | CN | claimed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | claimed |
| EP-1000062-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006409-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| US-7999107-B2 | Psychological disorders; cognition activators; Alzheimer's disease; headaches; nervous system antiinflammatory agents; antiepileptic agents; Parkinson's disease; Huntington's disease; schizophrenia; eating disorders | MERCK SHARP & DOHME CORP. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2109615-B1 | SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-2109615-A1 | SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| WO-2008094476-A1 | SUBSTITUTED PYRANO [2, 3 - B] PYRIDINE DERIVATIVES AS CANNABINOID -1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-6831079-B1 | Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone | AMERICAN CYANAMID COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1000062-B1 | TRICYCLIC VASOPRESSIN AGONISTS | WYETH CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | PIK3CA 1952/4885PIK3CD 2630/4885PIK3CB 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.